[O-33] Oral Session 33
Neuroimaging・Clinical trial　etc

[O-33-8] A Phase 2 Study of Galcanezumab in Japanese Patients with Episodic Migraine

^○Atsushi Kuga¹, Akichika Ozeki¹, Vladimir Skljarevski², Fumihiko Sakai³ (1.Eli Lilly Japan K.K., Kobe, Japan, 2.Eli Lilly and Company, Indianapolis, IN, USA, 3.Saitama Neuropsychiatric Institute, Saitama, Japan)